221 related articles for article (PubMed ID: 11002904)
1. Animal models of craving for ethanol.
Koob GF
Addiction; 2000 Aug; 95 Suppl 2():S73-81. PubMed ID: 11002904
[TBL] [Abstract][Full Text] [Related]
2. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
3. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Witkiewitz K; Bowen S; Donovan DM
J Consult Clin Psychol; 2011 Feb; 79(1):54-63. PubMed ID: 21261434
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic approaches to the management of alcoholism.
Anton RF
J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
[TBL] [Abstract][Full Text] [Related]
5. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.
Stromberg MF; Mackler SA; Volpicelli JR; O'Brien CP
Alcohol; 2001 Feb; 23(2):109-16. PubMed ID: 11331108
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
7. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.
Heyser CJ; Moc K; Koob GF
Neuropsychopharmacology; 2003 Aug; 28(8):1463-71. PubMed ID: 12700689
[TBL] [Abstract][Full Text] [Related]
8. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological validation of a new animal model of alcoholism.
Spanagel R; Hölter SM
J Neural Transm (Vienna); 2000; 107(6):669-80. PubMed ID: 10943907
[TBL] [Abstract][Full Text] [Related]
10. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Spanagel R; Zieglgänsberger W
Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
[TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone.
Dayas CV; Liu X; Simms JA; Weiss F
Biol Psychiatry; 2007 Apr; 61(8):979-89. PubMed ID: 17098214
[TBL] [Abstract][Full Text] [Related]
12. Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Czachowski CL; Delory MJ
Psychopharmacology (Berl); 2009 Jun; 204(2):335-48. PubMed ID: 19153715
[TBL] [Abstract][Full Text] [Related]
13. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Verheul R; Lehert P; Geerlings PJ; Koeter MW; van den Brink W
Psychopharmacology (Berl); 2005 Mar; 178(2-3):167-73. PubMed ID: 15322728
[TBL] [Abstract][Full Text] [Related]
14. Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.
Prisciandaro JJ; DeSantis SM; Chiuzan C; Brown DG; Brady KT; Tolliver BK
Alcohol Clin Exp Res; 2012 Mar; 36(3):490-6. PubMed ID: 21933201
[TBL] [Abstract][Full Text] [Related]
15. Association between a brief alcohol craving measure and drinking in the following week.
McHugh RK; Fitzmaurice GM; Griffin ML; Anton RF; Weiss RD
Addiction; 2016 Jun; 111(6):1004-10. PubMed ID: 26780476
[TBL] [Abstract][Full Text] [Related]
16. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.
Cole JC; Littleton JM; Little HJ
Psychopharmacology (Berl); 2000 Jan; 147(4):403-11. PubMed ID: 10672634
[TBL] [Abstract][Full Text] [Related]
17. Review: In alcohol use disorders, acamprosate is more effective for inducing abstinence while naltrexone is more effective for reducing heavy drinking and craving.
Soyka M
Evid Based Ment Health; 2013 Aug; 16(3):71. PubMed ID: 23604277
[No Abstract] [Full Text] [Related]
18. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
19. Effects of alcohol availability, access to alcohol, and naltrexone on self-reported craving and patterns of drinking in response to an alcohol-cue availability procedure.
Kruse MI; Radnovich AJ; Kalapatapu RK; Mehdiyoun N; Chambers RA; Davidson D
J Stud Alcohol Drugs; 2012 Mar; 73(2):205-15. PubMed ID: 22333328
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
